Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BriaCell Therapeutics Corp.BCTX · Entity 7454 | Director | August 01, 2022 | August 01, 2022 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BriaCell Therapeutics Corp.
Report date August 01, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24 · Expires 2026-03-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-08-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.47 · Expires 2027-01-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-08-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Option vests quarterly for 2 years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option vests quarterly for 2 years from the date of grant.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 452,667 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 454 · Balance 452,667 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 766 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F3: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Common StockSEC Table I · non-derivative | IndirectBy SQN LLC | 655,540 |
Reported balance
Holding disclosure · report date 2026-06-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 655,540 F2: The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 20:23 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 766 | $0.00 Strike: $499.86 | $0.00 |
DisclosureSEC source: 0001628280-26-044346 · wk-form4_1781814204.xml · derivative · entry 3 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766 Underlying: Common Stock · 766 shares Expires 2036-06-17 F3 · derivative.exercise_date: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:23 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-044346 · wk-form4_1781814204.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 452,667 F1 · kind: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| March 06, 2026 Filed Mar 6, 2026 23:07 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 491 | $431.94 | $212,082.54 |
DisclosureSEC source: 0001628280-26-015736 · wk-form4_1772838445.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 452,213 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| January 26, 2026 Filed Jan 26, 2026 22:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 647 | $492.42 | $318,595.74 |
DisclosureSEC source: 0001628280-26-003452 · wk-form4_1769465144.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 452,704 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 22:46 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,238 | $490.77 | $1,098,343.26 |
DisclosureSEC source: 0001628280-26-002735 · wk-form4_1768949160.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 453,351 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:38 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 240 | $0.00 Strike: $15.80 | $0.00 |
DisclosureSEC source: 0001628280-26-001970 · wk-form4_1768340287.xml · derivative · entry 5 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:38 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $551.24 | $110,248.40 |
DisclosureSEC source: 0001628280-26-001970 · wk-form4_1768340287.xml · nonDerivative · entry 3 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,589 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:38 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 40 | $545.79 | $21,831.60 |
DisclosureSEC source: 0001628280-26-001970 · wk-form4_1768340287.xml · nonDerivative · entry 2 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,789 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:38 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 240 | $15.80 | $3,792.00 |
DisclosureSEC source: 0001628280-26-001970 · wk-form4_1768340287.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,410 | $0.00 Strike: $15.80 | $0.00 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · derivative · entry 31 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 240 Underlying: Common Stock · 18,410 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F26 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 400 | $542.72 | $217,088.00 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 29 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,589 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 40 | $540.26 | $21,610.40 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 28 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,989 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 400 | $539.26 | $215,705.60 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 27 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,029 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F24 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.00 to $539.44, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 40 | $537.84 | $21,513.60 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 26 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,429 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 385 | $536.88 | $206,700.03 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 25 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,469 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F23 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.30, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 299 | $535.80 | $160,205.43 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 24 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,854 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F22 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.62 to $536.32, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 89 | $534.93 | $47,608.98 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 23 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,153 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.60 to $534.99, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 271 | $534.18 | $144,761.45 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 22 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,242 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.60 to $534.57, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 40 | $532.50 | $21,300.00 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 21 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,513 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 30 | $531.05 | $15,931.50 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 20 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,553 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 256 | $530.45 | $135,795.84 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 19 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,583 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.97 to $530.63, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 554 | $529.28 | $293,221.84 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 18 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,839 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.72 to $529.69, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 465 | $528.16 | $245,592.63 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 17 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,393 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.71 to $528.52, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,135 | $526.95 | $598,090.86 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 16 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,858 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.63 to $527.58, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 913 | $526.05 | $480,281.37 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 15 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 459,993 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.59 to $526.55, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,489 | $525.12 | $781,903.08 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 14 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 460,906 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $524.59 to $525.56, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,335 | $524.06 | $699,622.77 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 13 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 462,395 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $523.59 to $524.58, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 732 | $522.98 | $382,822.60 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 12 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,730 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $522.51 to $523.47, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 588 | $521.95 | $306,908.66 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 11 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,462 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $521.50 to $522.49, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 440 | $521.11 | $229,288.93 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 10 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,050 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $520.46 to $521.45, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 539 | $519.89 | $280,219.58 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 9 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,490 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.45 to $520.38, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 970 | $518.67 | $503,105.83 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 8 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,029 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.39 to $519.29, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,044 | $517.84 | $1,058,468.03 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 7 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,999 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.36 to $518.35, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 521 | $516.81 | $269,257.23 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 6 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 469,043 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.32 to $517.26, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,578 | $515.82 | $813,968.38 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 5 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 469,564 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.32 to $516.29, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 937 | $514.63 | $482,207.47 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 4 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,142 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.32 to $515.25, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 960 | $513.12 | $492,594.82 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 3 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 472,079 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.00 to $513.58, inclusive. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 960 | $512.02 | $491,537.18 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 2 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 473,039 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.71 to $512.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 18,410 | $15.80 | $290,878.00 |
DisclosureSEC source: 0001628280-26-001961 · wk-form4_1768340044.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 473,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,650 | $0.00 Strike: $15.80 | $0.00 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · derivative · entry 13 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,650 Underlying: Common Stock · 18,650 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GiftCommon Stock | 5,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 11 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,589 F10 · kind: The Reporting Person made a charitable contribution of 5,455 shares of common stock of the Issuer to a donor advised fund. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $555.39 | $111,078.00 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 10 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,044 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,027 | $554.84 | $569,822.43 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 9 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,244 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $554.39 to $555.31, inclusive. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,087 | $553.88 | $1,709,826.02 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 8 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 462,271 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.39 to $554.33, inclusive. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,857 | $552.81 | $2,132,196.66 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 7 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,358 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $552.39 to $553.38, inclusive. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 4,410 | $551.85 | $2,433,641.30 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 6 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 469,215 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.39 to $552.38, inclusive. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 4,723 | $550.99 | $2,602,307.35 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 5 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 473,625 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $550.39 to $551.38, inclusive. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 486 | $550.07 | $267,334.75 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 4 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,348 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.38 to $550.37, inclusive. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 369 | $548.56 | $202,417.87 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 3 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,834 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.17 to $549.00, inclusive. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 491 | $547.76 | $268,948.54 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 2 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 479,203 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.16 to $548.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.